The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2018 | AML complications: research into GvHD treatments
Florent Malard, MD, PhD, of Saint Antoine Hospital, Paris, France, discusses potential measures to improve the outcome of transplantation at the 2018 European Group for Blood and Marrow Transplantation (EMBT) Annual Meeting, held in Lisbon, Portugal. He emphasizes the need for further research into the impact of NKT cells on the complications of transplantation, namely graft-versus-host disease (GvHD). Dr Malard also discusses his team’s analysis comparing the use of anti-thymocite globulin (ATG)-based in vivo depletion and CD34 selected grafts with ex vivo depletion in patients with acute myeloid leukemia (AML) with GvHD.
